Epstein–Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features
Open Access
Abstract
Epstein–Barr virus (EBV) is a ubiquitous virus detected in up to 95% of the general population. Most people are asymptomatic, while some may develop a wide range of EBV-associated lymphoproliferative disorders (LPD). Among them, EBV-positive T/NK LPD are uncommon diseases defined by the proliferation of T- or NK-cells infected by EBV. The 2017 World Health Organization (WHO) classification recognizes the following entities characterized by different outcomes: chronic active EBV infection of T- or NK-cell types (cutaneous and systemic forms), systemic EBV-positive T-cell lymphoma of childhood, EBV-positive aggressive NK-cell leukemia, extra nodal NK/T-cell lymphoma nasal type, and the new provisional entity known as primary EBV-positive nodal T/NK-cell lymphoma. In addition, EBV associated-hemophagocytic lymphohistiocytosis is part of EBV-positive T/NK LPD, but has not been included in the WHO classification due to its reactive nature. Despite novel insights from high-throughput molecular studies, EBV-positive NK/T-cell LPD diagnoses remain challenging, especially because of their rarity and overlap. Until now, an accurate EBV-positive NK/T LPD diagnosis has been based on its clinical presentation and course correlated with its histological features. This review aims to summarize clinical, pathological and molecular features of EBV-positive T/NK LPD subtypes and to provide an overview of new understandings regarding these rare disorders.Keywords
This publication has 89 references indexed in Scilit:
- Extranodal NK/T-cell Lymphoma, Nasal TypeAmerican Journal of Surgical Pathology, 2013
- Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United StatesBlood, 2011
- XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative diseaseBlood, 2010
- Epstein-Barr Virus in Cutaneous T-Cell Lymphomas: Evaluation of the Viral Presence and Significance in Skin and Peripheral BloodJournal of Investigative Dermatology, 2009
- Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic featuresInternational Journal of Clinical Oncology, 2009
- A Clinical Study of 115 Patients with Extranodal Natural Killer/T-cell Lymphoma, Nasal TypeClinical Oncology, 2008
- Nasal NK/T-cell lymphoma: epidemiology and pathogenesisInternational Journal of Hematology, 2008
- Concomitant increase of LMP1 and CD25 (IL‐2‐receptor α) expression induced by IL‐10 in the EBV‐positive NK lines SNK6 and KAI3International Journal of Cancer, 2006
- Quantitative Analysis of Epstein‐Barr Virus (EBV)–Specific CD8+T Cells in Patients with Chronic Active EBV InfectionThe Journal of Infectious Diseases, 2004
- Hydroa vacciniforme: A clinical and follow-up study of 17 casesJournal of the American Academy of Dermatology, 2000